| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance.
The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods. During the fourth quarter, the Company billed 11,789 tissue-based units and 12,036 liquid-based units, representing growth of 50% and 10%, respectively. For the full year, the Company billed 41,586 tissue-based units and 45,700 liquid-based units, representing growth of 31% and 28%, respectively. Cash balance at year-end was $46.8 million.
The Company is also issuing 2025 revenue guidance of $108-110 million, which represents year-over-year growth of 20-22%, and confirms view of adjusted EBITDA profitability in the first half of this year.
Posted In: MDXH
